Sun Pharma: USFDA classifies Halol facility as Official Action Indicated Medical Dialogues Bureau30 March 2020 7:48 AM GMTMumbai: Sun Pharma has announced that the company has received communication from the USFDA indicating that the Halol facility has been classified as...
Aurobindo Pharma targets to achieve zero debt in three years sans Novartis deal Medical Dialogues Bureau26 Nov 2019 4:00 AM GMTIn September 2018, the USD three billion drug-maker, Aurobindo Pharma said its US subsidiary entered into an agreement to acquire commercial...
Torrent Pharma shares slump 3pc on USFDA warning letter for Gujarat facility Medical Dialogues Bureau11 Oct 2019 3:45 AM GMTTorrent Pharma does not believe that the warning letter will have an impact on the disruption of supplies or the existing revenues from operations of...
Cadila Healthcare gets OAI letter from USFDA for Moraiya facility Medical Dialogues Bureau8 Aug 2019 4:30 AM GMTThe company has received a letter from the USFDA classifying the inspection conducted at its Moraiya facility from April 22 to May 3 as OAI, Cadila...
Indoco Remedies: USFDA retains OAI status for Goa plant Farhat Nasim25 April 2019 4:20 AM GMTIndoco Remedies' spokesperson said that the move is likely to withhold approval of pending abbreviated new drug applications (ANDAs) from Goa...
Lupin Somerset facility gets OAI letter from USFDA Farhat Nasim18 March 2019 3:55 AM GMT"The USFDA has stated that this facility may be subject to regulatory or administrative action and that it may withhold approval of any pending...
USFDA Caution: Lupin gets OAI letter for MP plant Medical Dialogues Bureau17 March 2019 4:15 AM GMTLupin has received a letter from the US Food and Drug Administration (USFDA) classifying the inspection conducted at its Mandideep (Unit 1) facility...
